Reich, G;Cornely, OA;Sandherr, M;Kubin, T;Krause, S;Einsele, H;Thiel, E;Bellaire, T;Dörken, B;Maschmeyer, G.Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial..Br J Haematol.2005.130.2.265-70

Keller, U;Nilsson, JA;Maclean, KH;Old, JB;Cleveland, JL.Nfkb 1 is dispensable for Myc-induced lymphomagenesis..Oncogene.2005.24.41.6231-40

Nilsson, JA;Keller, UB;Baudino, TA;Yang, C;Norton, S;Old, JA;Nilsson, LM;Neale, G;Kramer, DL;Porter, CW;Cleveland, JL.Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation..Cancer Cell.2005.7.5.433-44

Schlenk, RF;Germing, U;Hartmann, F;Glasmacher, A;Fischer, JT;Fuentes, FDY;Götze, K;Pralle, H;Nerl, C;Salwender, H;Grimminger, W;Petzer, A;Hensel, M;Benner, A;Zick, L;Döhner, K;Frohling, S;Döhner, H.High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia.Leukemia.2005.19.6.978-983

Jörg, A;Grubert, T;Grimm, T;Guenzi, E;Naschberger, E;Samson, E;Oostendorp, R;Keller, U;Stürzl, M.Maternal HIV type 1 infection suppresses MMP-1 expression in endothelial cells of uninfected newborns: nonviral vertical transmission of HIV type 1-related effects..AIDS Res Hum Retroviruses.2005.21.11.940-4

Rondeau, G;McClelland, M;Nguyen, T;Risques, R;Wang, Y;Judex, M;Cho, AH;Welsh, J.Enhanced microarray performance using low complexity representations of the transcriptome..Nucleic Acids Res.2005.33.11.e100

Judex, MO;Mueller, BM.Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more..Am J Pathol.2005.166.3.645-7

Gilfillan, S;Stelzer, G;Piaia, E;Hofmann, MG;Meisterernst, M.Efficient binding of NC2.TATA-binding protein to DNA in the absence of TATA..J Biol Chem.2005.280.7.6222-30

Oostendorp, RA;Harvey, K;Dzierzak, EA.Generation of murine stromal cell lines: models for the microenvironment of the embryonic mouse aorta-gonads-mesonephros region..Methods Mol Biol.2005.290.163-72

Seufferlein, T;Dittrich, C;Riemann, J;Woell, E;Herrmann, T;Lordick, F;Arnold, D;Olchowka, K;Hoehler, T;Schmoll, HJ.A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor recepto.J Clin Oncol.2005.23.16.281S-281S